search
Back to results

The Effect of Nasal Hair on Nasal Obstruction

Primary Purpose

Nasal Obstruction

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vibrissae trimming
Application of oxymetazoline
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nasal Obstruction focused on measuring Nasal obstruction, Vibrissae, Nasal hair

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Presence of nasal vibrissae
  • Able to tolerate rhinomanometry

Exclusion Criteria:

  • Anatomical or other obvious cause of obstruction
  • Claustrophobia with rhinomanometry mask

Sites / Locations

  • Mayo Clinic in Rochester

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Vibrissae trimming

Arm Description

Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.

Outcomes

Primary Outcome Measures

Nasal airflow/pressure
Objective measures include airflow and pressure as assessed by Rhinomanometry.
Subjective Nasal Obstruction
Subjective measures will be assessed via the modified version of the NOSE outcome instrument-a validated test of subjective nasal obstruction

Secondary Outcome Measures

Full Information

First Posted
May 3, 2013
Last Updated
April 19, 2019
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT01850511
Brief Title
The Effect of Nasal Hair on Nasal Obstruction
Official Title
The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Nasal obstruction is a common complaint prompting presentation to an otolaryngologist. Many studies have been performed quantifying and describing the impact of a number of factors on symptoms of nasal obstruction, including anatomical, neoplastic, infectious, and inflammatory causes. Despite this scrutiny, no attention has been paid to the nasal vibrissae as a potential anatomical contributor to nasal obstruction. The proposed study intends to elucidate that contribution, if any exists.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasal Obstruction
Keywords
Nasal obstruction, Vibrissae, Nasal hair

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vibrissae trimming
Arm Type
Experimental
Arm Description
Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
Intervention Type
Procedure
Intervention Name(s)
Vibrissae trimming
Intervention Description
Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
Intervention Type
Drug
Intervention Name(s)
Application of oxymetazoline
Other Intervention Name(s)
Afrin
Intervention Description
Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
Primary Outcome Measure Information:
Title
Nasal airflow/pressure
Description
Objective measures include airflow and pressure as assessed by Rhinomanometry.
Time Frame
Participants will undergo assessment over a 30 minute period, no follow-up
Title
Subjective Nasal Obstruction
Description
Subjective measures will be assessed via the modified version of the NOSE outcome instrument-a validated test of subjective nasal obstruction
Time Frame
Participants will undergo assessment over a 30 minute period, no follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Presence of nasal vibrissae Able to tolerate rhinomanometry Exclusion Criteria: Anatomical or other obvious cause of obstruction Claustrophobia with rhinomanometry mask
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grant Hamilton, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21447962
Citation
Ozturk AB, Damadoglu E, Karakaya G, Kalyoncu AF. Does nasal hair (vibrissae) density affect the risk of developing asthma in patients with seasonal rhinitis? Int Arch Allergy Immunol. 2011;156(1):75-80. doi: 10.1159/000321912. Epub 2011 Mar 30.
Results Reference
background
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

The Effect of Nasal Hair on Nasal Obstruction

We'll reach out to this number within 24 hrs